We wish to inform you that the board of directors of Nectar Lifesciences Limited ( Company ) in their meeting held on Friday, January 23, 2026, have, inter-alia, noted, decided and approved the following matters:1. Approved the adoption of new set of Memorandum of Association ( MOA ) with amended object clause.2. Appointment of Internal Auditor for the financial year 2025-26 and 2026-27.3. To seek approval of shareholders through postal ballot process for adoption of new set of MOA with amended object clause of the Company.In accordance with the applicable laws and circulars thereunder, the Notice will be sent in electronic mode only to those members whose names appeared in the Register of Members/ List of Beneficial Owners maintained by the Company/ Depositories respectively as at close of business hours on Friday, January 23, 2026 ("Cut-off date").
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Nectar Lifesciences met on January 23, 2026, and approved the adoption of a new set of Memorandum of Association (MOA) with an amended object clause. The board also appointed an Internal Auditor for financial years 2025-26 and 2026-27. To make the MOA change effective, the company will seek shareholder approval through a postal ballot. Notices will be sent electronically only to members whose names appear in the records as of the January 23, 2026 cut-off date.
An amended object clause could indicate a planned expansion or shift in business activities, so investors should watch for further details on the new objects being added. The postal ballot outcome will determine if the change goes through, and shareholder participation will be key to the result.